HEPION PHARMACEUTICALS INC (HEPA)

Company Profile

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. The company is headquartered in Edison, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-02-07. The firm is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. The company is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. The company has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.

Company Info

HEPION PHARMACEUTICALS INC

399 Thornall St

Edison NEW JERSEY 08837

P: 17329024000

CEO: Robert Foster

Employees: 22

Website: https://hepionpharma.com/